MEG3 and prostate carcinoma: Moreover, a recent study revealed that lncRNA SNHG1 could promote cell progression by antagonizing miR‐199a‐3p in prostate cancer.10 Also, it has been found that MEG3 exerts its function through negatively regulating miR‐9 expression by directly interaction in vascular endothelial cells.19 In present study, we also found that MEG3 functions as a ceRNA for miR‐9‐5p in prostate cancer, which indicated that a mutual antagonism between MEG3 and miR‐9‐5p on impacting prostate cancer progression.